Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...

A new treatment vertical in eye care, pharmacologic agents for refractive correction, is in the early stage of ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

Credit: Alcon. The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors. Tryptyr significantly improved tear production compared with ...

The burden of presbyopia and reading glasses drives patients to look for solutions.“There is a clear and growing patient demand for noninvasive, reversible options to manage presbyopia,” Behnaz ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ...

BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved Oxervate TM (cenegermin-bkbj ophthalmic solution), a ...

Dexamethasone sodium phosphate 0.1%; oph soln; contains benzalkonium chloride. Initial therapy: 1 or 2 drops in conjunctival sac every hour during the day and every two hours during the night. When ...